PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1565660
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1565660
Oral Antiviral Market size was valued at USD 37,904.32 Million in 2023, expanding at a CAGR of 2.90% from 2024 to 2032.
The Oral Antiviral Market focuses on medications taken by mouth to treat viral infections, providing an accessible and convenient option for patients. The market is experiencing growth due to the increasing prevalence of viral diseases such as influenza, COVID-19, and herpes simplex. For example, the global market saw a notable rise in oral antiviral treatments with the approval of Paxlovid in 2021, which has been widely utilized for COVID-19 management. However, challenges such as high drug costs and concerns about long-term resistance can impede market growth. Opportunities lie in the development of next-generation oral antivirals with broader efficacy and lower resistance profiles. Additionally, the rising emphasis on personalized medicine and the expansion of healthcare access in emerging markets are contributing to the growth of oral antiviral therapies. The growing number of antiviral drugs in the pipeline and increasing investment in research and development further underscore the market's potential.
Oral Antiviral Market- Market Dynamics
Increasing Prevalence of Viral Diseases Boosts Growth in Oral Antiviral Market
The increasing prevalence of viral diseases is significantly driving the growth of the Oral Antiviral Market. According to the World Health Organization (WHO), influenza and COVID-19 remain major global health concerns, with millions affected annually. The U.S. Centers for Disease Control and Prevention (CDC) reported a surge in antiviral prescriptions during the COVID-19 pandemic, highlighting the critical role of oral antivirals in managing widespread infections. For instance, Paxlovid, an oral antiviral for COVID-19, was prescribed to over 500,000 patients in its first year of availability. Additionally, the rise in chronic viral conditions, such as herpes simplex, has increased the demand for effective oral treatments. As the global focus on combating viral diseases intensifies, advancements in antiviral drug development and expanding access to these medications are crucial factors driving market growth.
Oral Antiviral Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 2.90% over the forecast period (2024-2032)
Based on Type segmentation, Nucleoside Analogues were predicted to show maximum market share in the year 2023
Based on Route of Administration segmentation, Tablets was the leading type in 2023
Based on Application segmentation, COVID-19 was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Oral Antiviral Market is segmented on the basis of Type, Route of Administration, Application, End-User, and Region.
The market is divided into four categories based on Type: Nucleoside Analogues, Protease Inhibitors, Neuraminidase Inhibitors, and Polymerase Inhibitors. Nucleoside analogues lead the market due to their broad efficacy against various viral infections. Protease inhibitors follow, offering targeted action against specific viruses. Neuraminidase inhibitors are significant for influenza treatment, while polymerase inhibitors are crucial but less commonly used.
The market is divided into three categories based on Route of Administration: Tablets, Capsules, and Oral Suspensions. Tablets are the most popular route of administration due to their convenience and dosage accuracy. Capsules follow closely, offering similar benefits with a different format. Oral suspensions are used less frequently but are valuable for patients who have difficulty swallowing tablets or capsules.
Oral Antiviral Market- Geographical Insights
The Oral Antiviral Market shows distinct regional variations, with North America leading due to advanced healthcare systems and high drug adoption rates. In the U.S., the FDA's rapid approval of oral antivirals like Paxlovid during the COVID-19 pandemic led to widespread use, with over 10 million doses administered in the first year. Europe follows closely, where countries such as the UK and Germany have implemented comprehensive antiviral treatment programs, significantly increasing market demand. The European Medicines Agency (EMA) has supported this growth by fast-tracking approvals for new antiviral drugs. In the Asia-Pacific region, countries like Japan and India are experiencing rapid market expansion due to rising viral infection rates and increased healthcare investments. For instance, Japan's Ministry of Health has promoted the use of oral antivirals in managing influenza outbreaks. Latin America and the Middle East & Africa are also growing markets, driven by increasing healthcare infrastructure and rising awareness of antiviral treatments.
The Oral Antiviral Market is competitive, with major players actively engaging in strategic initiatives to maintain their market positions. Pfizer, a leading player, launched Paxlovid for COVID-19 and partnered with the Bill & Melinda Gates Foundation in 2022 to expand access to antiviral treatments in low-income countries. Merck & Co. has made headlines with its Molnupiravir for COVID-19, and in 2021, it collaborated with Ridgeback Biotherapeutics to accelerate its development and distribution. Gilead Sciences, known for Veklury (remdesivir), has continued to innovate and expand its antiviral portfolio. Additionally, Roche Holdings acquired the antiviral company TIB Molbiol in 2023 to strengthen its position in viral diagnostics and treatments. These companies are leveraging partnerships, acquisitions, and collaborations to enhance their antiviral offerings and address the growing global demand for effective oral antiviral therapies.
In November 2021, Pfizer's investigational COVID-19 oral antiviral, PAXLOVID(TM), demonstrated an 89% reduction in hospitalization or death risk in high-risk adults during a Phase 2/3 study. The company plans to submit data to the FDA for Emergency Use Authorization soon.
In October 2021, Merck and Ridgeback Biotherapeutics announced that their investigational oral antiviral, molnupiravir, reduced the risk of hospitalization or death by about 50% in mild to moderate COVID-19 patients. They plan to seek Emergency Use Authorization from the FDA based on these results.